Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

Latest News

3 min read

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma...

Read More
JULY 6, 2022
3 min read

KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland

The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the...

Read More
MAY 11, 2022
4 min read

Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year

Geneva, Switzerland, May 11, 2022Selexis SA, a JSR Life Sciences Company, announced today that Great Place to Work®...

Read More